Membranous nephropathy: high-dose alternate-day therapy with prednisone

Area of Science:

• Nephrology
• Internal Medicine

Background:

• Membranous nephropathy is a leading cause of nephrotic syndrome in adults.
• Disease progression and renal insufficiency are common complications.
• Effective treatment strategies for membranous nephropathy remain an area of active research.

Purpose of the Study:

• To evaluate the efficacy of alternate-day prednisone treatment in patients with membranous nephropathy.
• To assess the impact of prednisone on proteinuria, albumin levels, and renal function.
• To determine the rate of healing and attainment of normal renal function.

Main Methods:

• Retrospective study of 15 patients with biopsy-proven membranous nephropathy.
• Patients served as their own controls during a pretreatment observation period.
• Treatment involved alternate-day administration of prednisone.
• Outcomes assessed included proteinuria, serum albumin, and creatinine clearance.

Main Results:

• All patients experienced decreased proteinuria and increased serum albumin levels with prednisone treatment.
• Eight out of 15 patients achieved healing, defined as sustained low proteinuria and normal creatinine clearance.
• Renal function improved in all 11 patients with initial renal insufficiency, with eight achieving normal function.
• Poor renal function was not linked to diminished blood volume.

Conclusions:

• Alternate-day prednisone therapy is an effective treatment for membranous nephropathy.
• This treatment can lead to significant improvements in proteinuria, albumin levels, and renal function.
• Prednisone offers a viable therapeutic option for patients with membranous nephropathy, potentially leading to disease remission.